Quantum-Si Inc Ordinary Shares - Class A QSI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if QSI is a good fit for your portfolio.
News
-
Quantum-Si Reports First Quarter 2024 Financial Results
-
Quantum-Si Announces Upgrades to Analysis Software that will Provide Customers with Higher Data Output and Precision and Shorter Processing Time
-
Quantum-Si to Report First Quarter 2024 Financial Results on May 9, 2024
-
Quantum-Si Appoints Former Illumina and Cisco Systems Executive, Paula Dowdy, to its Board of Directors
-
Thinking about buying stock in CureVac, Quantum-Si, Clearone, Rambus, or Generation Bio?
-
Thinking about buying stock in Quantum-Si, Victoria's Secret, Viracta Therapeutics, CERo Therapeutics, or Weyerhaeuser?
-
Quantum-Si and Researchers to Highlight the Power of Next-Generation Protein Sequencing™ on Platinum® at US HUPO Conference
-
Quantum-Si Reports Fourth Quarter and Full Year 2023 Financial Results
Trading Information
- Previous Close Price
- $1.86
- Day Range
- $1.77–1.87
- 52-Week Range
- $1.12–3.90
- Bid/Ask
- $1.77 / $1.78
- Market Cap
- $251.72 Mil
- Volume/Avg
- 107,806 / 750,546
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 205.07
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Quantum-Si Inc is focused on revolutionizing the growing field of proteomics. The company's suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable single-molecule next-generation protein sequencing and genomics, and digitize proteomic research in order to advance drug discovery and diagnostics beyond DNA sequencing.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 165
- Website
- https://www.quantum-si.com
Comparables
Valuation
|
Metric
|
QSI
|
TIHE
|
VCYT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 27.27 |
Price/Book Value | 1.04 | — | 1.60 |
Price/Sales | 205.07 | — | 4.57 |
Price/Cash Flow | — | — | 31.78 |
Price/Earnings
QSI
TIHE
VCYT
Financial Strength
|
Metric
|
QSI
|
TIHE
|
VCYT
|
|---|---|---|---|
Quick Ratio | 29.56 | — | 4.41 |
Current Ratio | 30.65 | — | 5.00 |
Interest Coverage | — | — | −11,324.57 |
Quick Ratio
QSI
TIHE
VCYT
Profitability
|
Metric
|
QSI
|
TIHE
|
VCYT
|
|---|---|---|---|
Return on Assets (Normalized) | −27.45% | — | 8.19% |
Return on Equity (Normalized) | −29.81% | — | 8.76% |
Return on Invested Capital (Normalized) | −31.82% | — | 7.87% |
Return on Assets
QSI
TIHE
VCYT
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Ngwbhwchz | Ytk | $593.5 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Gmsbpqzmp | Jxxbgg | $113.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Nlgdyljhs | Pplght | $106.7 Bil | |
MRNA
| Moderna Inc | Ppfzbwnd | Gzq | $50.8 Bil | |
BNTX
| BioNTech SE ADR | Vfpfpbx | Vtl | $22.4 Bil | |
ARGX
| argenx SE ADR | Mrkrvphx | Bfclq | $22.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xlwwlcrxw | Wlwllcc | $19.1 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Kbstpfdq | Jbbmh | $14.6 Bil | |
INCY
| Incyte Corp | Hxpstrlcj | Fmqwvn | $12.8 Bil | |
RPRX
| Royalty Pharma PLC Class A | Gmdnkkkjm | Kmvncb | $12.6 Bil |